Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

MARION, SQUIBB AND ALZA LEAD PHARMACEUTICALS AS INDEX STOCKS JOIN RALLY Paced by Marion (up 4-1/4 to 37), Squibb (up 4-3/8 to 61-7/8) and Syntex (up 3-1/4 to 60-3/8), Pharmaceutical stocks were the big gainers on the "F-D-C" Index for the week ended May 10, rising 2.7% overall. Also joining the rally, Bolar (up 1-7/8 to 43-5/8) continued to exhibit the investor excitement over generic companies that began last year. The Index Composite echoed the Dow Jones' 2.2% gain -- the market's first sustained advance in almost six weeks. Overall, gains outnumbered declines on the 51-issue index by almost four to one. Diversifieds as a group rose slightly more than 2%. Big movers included Forest (up 2-1/2 to 21-7/8), Revlon (up 2-1/4 to 38-3/8), American Home Products (up 2-5/8 to 61-3/4) and Pfizer (up 2 to 46-7/8). Drug chains, while not exhibiting as strong gains as pharmaceuticals and diversifieds, nevertheless posted a solid 1.6% gain, with seven of 10 stocks rising. The big loser for the week was Jack Eckerd, which dropped 3-1/2 points to 22-7/8 after the company predicted a 50% decline in net earnings for the third quarter. Chart omitted.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts